News and Trends 21 Jun 2022 Drug to treat esophageal cancer approved in China A new drug application for first-line treatment of unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) has been approved in China. Biopharmaceutical company Innovent Biologics Inc together with Eli Lilly and Company were jointly granted the approval for the supplemental new drug application for TYVYT, a sintilimab injection, combined with cisplatin plus […] June 21, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jun 2022 New data demonstrates clinical potential of Inivata’s RaDaR technology for breast cancer Data supporting the detection of minimal residual disease (MRD) has highlighted potential to provide an early predictor of tumor recurrence in patients who have had breast cancer. Liquid biopsy company Inivata announced the new data in support of its new RaDaR assay for the detection of MRD in those with high-risk hormone receptor-positive (HR+), human […] June 21, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jun 2022 Elypta raises $21M to develop early detection test for all cancers Elypta, a Swedish diagnostics company aiming to commercialize the first metabolism-based liquid biopsy for early detection of any cancer, has raised $21 million in a series A financing round led by Bonnier Ventures. “The series A is a pivotal moment for Elypta as it fully funds the development of our two leading indications,” said Karl […] June 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jun 2022 Immuneel Therapeutics raises $15M and starts patient trials for CAR-T cancer therapies Indian biotech start-up Immuneel Therapeutics has announced it has started patient dosing in a CAR-T trial named “IMAGINE.” The Indian company focuses on creating access to Chimeric Antigen Receptor T cell therapy (CAR-T) and other cellular immunotherapies for the management and treatment of cancers. The phase II trial is the first industry sponsored CAR-T trial […] June 21, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jun 2022 ImCheck raises €96M in funding round French biotech company ImCheck has announced funding of €96 million ($101.5 million) to investigate antibody drugs with the ability to activate the powerful immune cells called gamma delta T (gdT). The Marseille-based company hopes it will reach a wider range of cancer immunotherapy with the antibody drugs that include a lead candidate in the development […] June 17, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jun 2022 Spirea raises £2.4M to develop antibody drug conjugates in cancer Funding of £2.4 million ($2.9 million) has been secured by UK-based company, Spirea Limited, to advance a new generation of antibody drug conjugate (ADC) therapeutics. The company will use the funds to initiate its pipeline of ADCs in the treatment of solid tumors where they say there is a high unmet need. Targeted therapies, especially […] June 16, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2022 TILT Biotherapeutics raises $10M to push ahead on cancer immunotherapies TILT Biotherapeutics (TILT), a clinical-stage Finnish biotech company developing cancer immunotherapies, has completed the first close of its financing round, raising $10.7 million. It was led by Lifeline Ventures and joined by Tesi (Finnish Industry Investment Ltd). The funding will be used to advance phase I/II programs in Europe and the U.S., using TILT-123 plus […] June 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jun 2022 Amaroq Therapeutics ‘hits early milestones’ in cancer treatment New Zealand biotech company Amaroq Therapeutics said it is progressing towards clinical trials following a promising initial development phase. The company, a start-up spun out of the University of Otago, is focused on developing a new class of therapeutics that target long non-coding RNAs (lncRNA) in cancer. Sarah Diermeier, chief scientific officer and founder of […] June 9, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2022 Neuroendocrine cancer under the spotlight as Ariceum Therapeutics launches Ariceum Therapeutics, a private biotech company developing a radiopharmaceutical product for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, has completed an oversubscribed €25M ($26.7M) Series A financing round. Ariceum was co-founded by EQT Life Sciences (formerly LSP) and HealthCap, which also co-led the financing that was joined by Pureos Bioventures. Ipsen […] June 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jun 2022 Cancer vaccine biotech CimCure raises €5M Dutch biotech company CimCure, which is focusing on the development of vaccine-based cancer immunotherapy, has raised more than €5M ($5.3M) in a financing seed round led by Dutch company Positron Ventures. CimCure, a spin-off of the Amsterdam UMC medical center, is set to use the funds to advance its vaccine up to phase 1-2 clinical […] June 7, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jun 2022 ImmunOs Therapeutics raises $74M ImmunOs Therapeutics AG, a biopharmaceutical company developing therapeutics for the treatment of cancer and autoimmune diseases, has announced the closing of an oversubscribed Series B financing round totaling $74M. The round was led by new investors Samsara BioCapital, Lightspeed Venture Partners, and Gimv, and joined by other new investors Mission BioCapital, GL Capital, PEAK6 Strategic […] June 7, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2022 ANGLE and U.S. urology group to undertake prostate cancer study ANGLE plc has signed a master clinical study agreement with Solaris Health Holdings, LLC and joinder agreements with MidLantic Urology LLC, to collaborate and conduct clinical studies in prostate cancer and as a potential route to market in the U.S. Alongside Solaris affiliate MidLantic Urology, UK-headquartered ANGLE will initiate clinical studies aimed at detecting prostate […] May 31, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email